ArriVent BioPharma, Inc.
NASDAQArriVent BioPharma heads into its August 13 earnings event with one of the more charged short setups in clinical-stage biotech — nearly one in five float shares is held short, and the ORTEX short score is running at an elevated 78.8. Short sellers have built a substantial position: short interest is 18.7% of the free float, a level that reflects deep scepticism about the binary…
Snapshot as of 27 Sept 2026
ArriVent BioPharma heads into its August 13 earnings event with one of the more charged short setups in clinical-stage biotech — nearly one in five float shares is held short, and the ORTEX short score is running at an…
ArriVent BioPharma heads into the week of May 18 carrying three fresh catalysts — a Q1 EPS miss, a $250 million at-the-market equity offering, and a Citigroup target cut — yet short sellers have been quietly reducing…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AVBP — free to start on ORTEX.
Sign up for free →Open AVBP on ORTEX